Targeting the stromal fibroblasts: a novel approach to melanoma therapy

References

• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br. J. Dermatol.146(Suppl. 61), S1–S6 (2002).
   PubMed Web of Science ®Google Scholar
• Marks R. Epidemiology of melanoma. Clin. Exp. Dermatol. 25(6), 459–463 (2000).
   PubMedGoogle Scholar
• Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12(1), 69–82 (2001).
   PubMed Web of Science ®Google Scholar
• Bishop DT, Demenais F, Goldstein AM et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst.94(12), 894–903 (2002).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Smalley KSM. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer104(5), 527–532 (2003).
   PubMed Web of Science ®Google Scholar
• Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res.10(1), 81–92 (2000).
   PubMed Web of Science ®Google Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J. Exp. Clin. Cancer Res. 19(1), 21–34 (2000).
   PubMed Web of Science ®Google Scholar
• Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 22(20), 3138–3151 (2003).
   PubMed Web of Science ®Google Scholar
• Labrousse AL, Ntayi C, Hornebeck W, Bernard P. Stromal reaction in cutaneous melanoma. Crit. Rev. Oncol. Hematol. 49(3), 269–275 (2004).
   PubMedGoogle Scholar
• Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma–stroma interactions: structural and functional aspects. Lancet Oncol. 3(1), 35–43 (2002).
   PubMed Web of Science ®Google Scholar
• Bissell MJ, Radisky D. Putting tumors in context. Nature Rev. Cancer 1(1), 46–54 (2001).
   PubMed Web of Science ®Google Scholar
• Nakhleh RE, Wick MR, Rocamora A, Swanson PE, Dehner LP. Morphologic diversity in malignant melanomas. Am. J. Clin. Pathol.93(6), 731–740 (1990).
   PubMed Web of Science ®Google Scholar
• Banerjee SS, Harris M. Morphological and immunophenotypic variations in malignant melanoma. Histopathology 36(5), 387–402 (2000).
   PubMed Web of Science ®Google Scholar
• Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34(3), 255–268 (2002).
   PubMed Web of Science ®Google Scholar
• Haass NK, Smalley KSM, Herlyn M. The role of altered cell–cell communication in melanoma progression. J. Mol. Hist. 35(3), 309–318 (2004).
   PubMed Web of Science ®Google Scholar
• Tang A, Eller MS, Hara M et al. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J. Cell. Sci. 107(Pt 4), 983–992 (1994).
   PubMedGoogle Scholar
• Hsu MY, Meier FE, Nesbit M et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am. J. Pathol. 156(5), 1515–1525 (2000).
   PubMed Web of Science ®Google Scholar
• Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61(9), 3819–3825 (2001).
   PubMed Web of Science ®Google Scholar
• Smalley KSM, Brafford P, Haass NK et al. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am. J. Pathol. 166(5), 1541–1554 (2005).
   PubMedGoogle Scholar
• Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315(26), 1650–1659 (1986).
   PubMed Web of Science ®Google Scholar
• Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264(1), 169–184 (2001).
   PubMed Web of Science ®Google Scholar
• Nakayama H, Enzan H, Miyazaki E et al. The role of myofibroblasts at the tumor border of invasive colorectal adenocarcinomas. Jpn J. Clin. Oncol. 28(10), 615–620 (1998).
   PubMedGoogle Scholar
• Tsukamoto H, Mishima Y, Hayashibe K, Sasase A. α-Smooth muscle actin expression in tumor and stromal cells of benign and malignant human pigment cell tumors. J. Invest. Dermatol. 98(1), 116–120 (1992).
   PubMed Web of Science ®Google Scholar
• Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer107(1), 1–10 (2003).
   PubMed Web of Science ®Google Scholar
• Mori L, Bellini A, Stacey MA, Schmidt M, Mattoli S. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp. Cell Res. 304(1), 81–90 (2005).
   PubMed Web of Science ®Google Scholar
• De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J. Pathol. 200(4), 429–447 (2003).
   PubMed Web of Science ®Google Scholar
• Direkze NC, Hodivala-Dilke K, Jeffery R et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64(23), 8492–8495 (2004).
   PubMed Web of Science ®Google Scholar
• Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425(6958), 577–584 (2003).
   PubMed Web of Science ®Google Scholar
• Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19(38), 4337–4345 (2000).
   PubMed Web of Science ®Google Scholar
• Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl Acad. Sci. USA 95(3), 1050–1055 (1998).
   PubMedGoogle Scholar
• D’Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am. J. Pathol. 158(6), 2031–2041 (2001).
   PubMedGoogle Scholar
• Rockey DC, Chung JJ. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J. Clin. Invest. 98(6), 1381–1388 (1996).
   PubMedGoogle Scholar
• Ronnov-Jessen L, Petersen OW. Induction of α-smooth muscle actin by transforming growth factor-β 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 68(6), 696–707 (1993).
   PubMed Web of Science ®Google Scholar
• Garinchesa P, Old LJ, Rettig WJ. Cell-surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl Acad. Sci. USA 87(18), 7235–7239 (1990).
   PubMedGoogle Scholar
• Rettig WJ, Garinchesa P, Beresford HR et al. Cell-surface glycoproteins of human sarcomas – differential expression in normal and malignant-tissues and cultured-cells. Proc. Natl Acad. Sci. USA 85(9), 3110–3114 (1988).
   PubMed Web of Science ®Google Scholar
• Huber MA, Kraut N, Park JE et al. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J. Invest. Dermatol. 120(2), 182–188 (2003).
   PubMed Web of Science ®Google Scholar
• Ramirez-Montagut T, Blachere NE, Sviderskaya EV et al. FAP-α, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 23(32), 5435–5446 (2004).
   PubMed Web of Science ®Google Scholar
• Gallagher PG, Bao YD, Prorock A et al. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host–tumor interactions in metastasis. Cancer Res. 65(10), 4134–4146 (2005).
   PubMed Web of Science ®Google Scholar
• Krasagakis K, Kruger-Krasagakes S, Fimmel S et al. Desensitization of melanoma cells to autocrine TGF-β isoforms. J. Cell. Physiol. 178(2), 179–187 (1999).
   PubMedGoogle Scholar
• VanBelle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-β isoforms. Am. J. Pathol. 148(6), 1887–1894 (1996).
   PubMedGoogle Scholar
• Berking C, Takemoto R, Schaider H et al. Transforming growth factor-β 1 increases survival of human melanoma through stroma remodeling. Cancer Res. 61(22), 8306–8316 (2001).
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 276(20), 17058–17062 (2001).
   PubMed Web of Science ®Google Scholar
• Meier F, Nesbit M, Hsu MY et al. Human melanoma progression in skin reconstructs – biological significance of bFGF. Am. J. Pathol. 156(1), 193–200 (2000).
   PubMed Web of Science ®Google Scholar
• Micke P, Ostman A. Tumour–stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45(Suppl. 2), S163–S175 (2004).
   PubMedGoogle Scholar
• Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and β-catenin pathways. Cancer Res. 61(19), 7318–7324 (2001).
   PubMed Web of Science ®Google Scholar
• Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ. 13(2), 87–93 (2002).
   PubMedGoogle Scholar
• Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3), 335–348 (2005).
   PubMed Web of Science ®Google Scholar
• Cornil I, Theodorescu D, Man S et al. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc. Natl Acad. Sci. USA 88(14), 6028–6032 (1991).
   PubMedGoogle Scholar
• De Wever O, Nguyen QD, Van Hoorde L et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 18(6), 1016–1018 (2004).
   PubMed Web of Science ®Google Scholar
• Edward M, Gillan C, Micha D, Tammi RH. Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumor growth and invasion. Carcinogenesis 26(7), 1215–1223 (2005).
   PubMedGoogle Scholar
• Liotta LA, Kohn EC. The microenvironment of the tumor–host interface. Nature 411(6835), 375–379 (2001).
   PubMed Web of Science ®Google Scholar
• Loffek S, Zigrino P, Angel P et al. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1 α and basic fibroblast growth factor-mediated mechanisms. J. Invest. Dermatol. 124(3), 638–643 (2005).
   PubMedGoogle Scholar
• Opdenakker G, Van Damme J. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int. J. Dev. Biol. 48(5–6), 519–527 (2004).
   PubMedGoogle Scholar
• Liu ZJ, Snyder R, Soma A et al. VEGF-A and α(V)β(3) integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. FASEB J. 17(11), 1931–1933 (2003).
   PubMed Web of Science ®Google Scholar
• Velazquez OC, Snyder R, Liu ZJ, Fairman RM, Herlyn M. Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like, three-dimensional networks. FASEB J. 16(8), 1316–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Meredith JE, Fazeli B, Schwartz MA. The extracellular-matrix as a cell-survival factor. Mol. Biol. Cell 4(9), 953–961 (1993).
   PubMed Web of Science ®Google Scholar
• Frisch SM, Screaton RA. Anoikis mechanisms. Curr. Opin. Cell Biol. 13(5), 555–562 (2001).
   PubMed Web of Science ®Google Scholar
• Kraus AC, Ferber I, Bachmann SO et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAPK pathways. Oncogene 21(57), 8683–8695 (2002).
   PubMed Web of Science ®Google Scholar
• Sethi T, Rintoul RC, Moore SM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med. 5(6), 662–668 (1999).
   PubMed Web of Science ®Google Scholar
• Berube M, Talbot M, Collin C et al. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin. Int. J. Oncol. 26(2), 405–413 (2005).
   PubMedGoogle Scholar
• Giannelli G, Azzariti A, Fransvea E et al. Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells. Br. J. Cancer 91(11), 1964–1969 (2004).
   PubMed Web of Science ®Google Scholar
• Narita T, Kimura N, Sato M, Matsuura N, Kannagi R. Altered expression of integrins in adriamycin-resistant human breast cancer cells. Anticancer Res. 18(1A), 257–262 (1998).
   PubMedGoogle Scholar
• Folkman J, Moscona A. Role of cell-shape in growth-control. Nature 273(5661), 345–349 (1978).
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Chytil A, Plieth D et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303(5659), 848–851 (2004).
   PubMed Web of Science ®Google Scholar
• Olumi AF, Grossfeld GD, Hayward SW et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59(19), 5002–5011 (1999).
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60(5), 1254–1260 (2000).
   PubMed Web of Science ®Google Scholar
• Ohuchida K, Mizumoto K, Murakami M et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor–stromal interactions. Cancer Res. 64(9), 3215–3222 (2004).
   PubMed Web of Science ®Google Scholar
• Hu M, Yao J, Cai L et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genet. 37(8), 899–905 (2005).
   PubMed Web of Science ®Google Scholar
• Illmensee K, Mintz B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl Acad. Sci. USA 73(2), 549–553 (1976).
   PubMed Web of Science ®Google Scholar
• Mintz B, Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA 72(9), 3585–3589 (1975).
   PubMed Web of Science ®Google Scholar
• Weaver VM, Petersen OW, Wang F et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137(1), 231–245 (1997).
   PubMed Web of Science ®Google Scholar
• Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2(9), 657–672 (2002).
   PubMed Web of Science ®Google Scholar
• Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nature Rev. Mol. Cell Biol. 3(3), 207–214 (2002).
   PubMed Web of Science ®Google Scholar
• Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7(6), 513–520 (2005).
   PubMed Web of Science ®Google Scholar
• Posey JA, Khazaeli MB, DelGrosso A et al. A pilot trial of Vitaxin®, a humanized anti-vitronectin receptor (anti-α v β 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. 16(2), 125–132 (2001).
   PubMed Web of Science ®Google Scholar
• Sawyers C. Targeted cancer therapy. Nature 432(7015), 294–297 (2004).
   PubMed Web of Science ®Google Scholar
• Dumont N, Arteaga CL. Targeting the TGF β signaling network in human neoplasia. Cancer Cell 3(6), 531–536 (2003).
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Nicoletti G et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65(9), 3868–3876 (2005).
   PubMed Web of Science ®Google Scholar
• Min Y, Adachi Y, Yamamoto H et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumor growth in human gastric cancer xenografts. Gut 54(5), 591–600 (2005).
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291(1), 367–373 (1999).
   PubMed Web of Science ®Google Scholar
• Scott AM, Wiseman G, Welt S et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9(5), 1639–1647 (2003).
   PubMed Web of Science ®Google Scholar